EYA4: A Potential Drug Target and Biomarker for Multiple Chronic Diseases

Target Name: EYA4

NCBI ID: G2070

EYA4

EYA4: A Potential Drug Target and Biomarker for Multiple Chronic Diseases

EGF-related signaling pathways have been implicated in various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases. The extracellular domain (ECD) of the epidermal growth factor receptor (EGFR) has been identified as a promising target for anti-cancer and anti-inflammatory drugs. One of its isoforms, EYA4 (EYA4 variant 1), has been shown to be overexpressed or hypermethylated in various diseases, including neurodegenerative disorders, cancer, and autoimmune diseases. In this article, we discuss the potential implications of EYA4 as a drug target and biomarker for multiple chronic diseases.

Overview of EYA4

EYA4 is a 21-kDa transmembrane protein that belongs to the EGF receptor family. It is the most abundant EGFR isoform in the human body, accounting for up to 80% of the total EGFR protein. EYA4 has four splice variants, each with a different amino acid sequence at its C-terminus. EYA4 variants have been implicated in various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases.

Expression and Function of EYA4

EYA4 is highly expressed in various tissues and organs, including the brain, pancreas, muscle, liver, and cervical cancer. It is also expressed in various cell types, including epithelial and endothelial cells, smooth muscle cells, and immune cells. EYA4 has been shown to play a role in various cellular processes, including cell signaling, cell migration, and angiogenesis.

In neurodegenerative disorders, EYA4 has been shown to be involved in the development and progression of neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. EYA4 has also been shown to be involved in the regulation of pain perception and neuroinflammation.

In cancer, EYA4 has been shown to be involved in the development and progression of various types of cancer, including lung, breast, and colorectal cancer. It has also been shown to play a role in the regulation of cell proliferation and angiogenesis.

In autoimmune diseases, EYA4 has been implicated in the development and progression of autoimmune diseases, including rheumatoid arthritis, lupus, and multiple sclerosis. It has also been shown to play a role in the regulation of immune cell function and the regulation of inflammation.

Potential Therapeutic Applications of EYA4

The potential therapeutic applications of EYA4 are vast and varied. One of the most promising applications is the development of anti-cancer and anti-inflammatory drugs that target EYA4. These drugs could be used to treat various types of cancer, including lung, breast, and colorectal cancer, as well as neurodegenerative disorders, such as Alzheimer's disease, Parkinson's disease, and Huntington's disease.

Another potential application of EYA4 is the development of drugs that target EYA4-related signaling pathways. These drugs could be used to treat various types of neurodegenerative disorders, including Alzheimer's disease, Parkinson's disease, and Huntington's disease.

In addition to these applications, EYA4 may also be used as a biomarker for various types of cancer and neurodegenerative disorders. These biomarkers could be used to diagnose and monitor the progression of these diseases.

Conclusion

EYA4 is a protein that has been shown to be involved in various cellular processes in the body. It is highly expressed in various tissues and organs, including the brain, pancreas, muscle, liver, and cervical cancer. In addition to its role in cell signaling and angiogenesis, EYA4 has also been shown to play a role in the regulation of pain perception and neuroinflammation.

The potential therapeutic applications of EYA4 are vast and varied. It has been shown to be involved in the development and progression of various types of cancer, including lung, breast, and colorectal cancer, as well as neurodegenerative disorders. In addition to these applications, EYA4 may also be used as a biomarker for various types of cancer and neurodegenerative disorders.

Overall, the study of EYA4 is an exciting and promising area of research. Further studies are needed to fully understand its role in various cellular processes and its potential as a drug target and biomarker for multiple chronic diseases.

Protein Name: EYA Transcriptional Coactivator And Phosphatase 4

Functions: Tyrosine phosphatase that specifically dephosphorylates 'Tyr-142' of histone H2AX (H2AXY142ph). 'Tyr-142' phosphorylation of histone H2AX plays a central role in DNA repair and acts as a mark that distinguishes between apoptotic and repair responses to genotoxic stress. Promotes efficient DNA repair by dephosphorylating H2AX, promoting the recruitment of DNA repair complexes containing MDC1. Its function as histone phosphatase probably explains its role in transcription regulation during organogenesis. May be involved in development of the eye (By similarity)

The "EYA4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about EYA4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets